Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema
NCT ID: NCT07106268
Last Updated: 2025-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
100 participants
OBSERVATIONAL
2023-03-01
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers and Choroidal Neovascularization
NCT04439708
Aqueous Vascular Endothelial Growth Factor (VEGF) Levels in Type 3 Neovascularization
NCT01350323
Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion
NCT04812977
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
NCT03971162
The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma
NCT03154892
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with central retinal vein occlusion
Received three injections of the anti-VEGF drug Conbercept
No interventions assigned to this group
Patients with branch retinal vein occlusion
Received three injections of the anti-VEGF drug Conbercept
No interventions assigned to this group
Cataract patients without other eye diseases and other chronic diseases
Undergo cataract surgery
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened
* Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm
* Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery
* The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram
Exclusion Criteria
* Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases
* Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study
20 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University Eye Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chuanzhen Zheng
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin medical university eye hospital
Tianjin, Province, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MR-12-24-035937
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.